Therapy Areas: Cardiovascular
Circio and AaviGen partner to develop next-generation gene therapies for heart disease
27 May 2026 - Biotechnology companies Circio Holding ASA (OSE:CRNA) and AaviGen GmbH on Wednesday announced a research collaboration to develop circVec-enhanced AAV vectors engineered for targeted, lo...
Eli Lilly reports positive Phase 1b results for VERVE-102
26 May 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Monday reported positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine desi...
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
21 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted Priority Rev...
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
18 May 2026 - Endospan, a pioneer in endovascular solutions for complex aortic pathologies, announced on Monday that it has been acquired by medical device company Artivion Inc (NYSE: AORT) following ...
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
18 May 2026 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (NYSE: AZN) reported on Monday that it has received US Food and Drug Administration approval for Baxfendy (baxdrostat), th...
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, t...